Incretin-based Therapy in Preclinical Type 1 Diabetes in Adults

NCT02611232 · Unknown status

Last updated 2026-05-28

This clinical trial is testing whether a type of incretin-based therapy can help preserve insulin production in adults who are in the early stages of type 1 diabetes.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind prevention study

Participants 42 people Planned (estimated).

Who can join Ages 18–30 · all sexes

Timeline Started 2015-12 · est. completion 2024-06

Where 3 sites · Finland

What this study is testing ClinicalTrials.gov NCT02611232 ↗

Description as written by the study sponsor.

The main objectives of the trial are to study whether daily treatment with liraglutide improves insulin secretion and glucose metabolism, and whether liraglutide treatment is tolerable and safe in subjects with preclinical type 1 diabetes aged 18-30 years.

Treatments tested

Victoza® Drug

Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 24 months.
Placebo Drug

Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 24 months.

Main thing measured	FPIR (first phase insulin response)
Sponsor	University of Oulu
Conditions studied	Type 1 Diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02611232 ↗